Abstract
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Hematologic Diseases / complications*
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Middle Aged
-
Palivizumab
-
Pneumonia / drug therapy
-
Pneumonia / virology
-
Respiratory Syncytial Virus Infections / drug therapy*
-
Respiratory Tract Infections / drug therapy*
-
Respiratory Tract Infections / virology
-
Retrospective Studies
-
Survival Analysis
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Palivizumab